Market Cap: $240.39M
CI
Capricor Therapeutics, Inc.
CAPR
NASDAQUSD
Market Cap: $240.39M
Capricor Therapeutics, Inc. ( CAPR ) is drawing attention as the latest developments come into focus. Capricor Therapeutics, Inc. (CAPR) faces pivotal challenges as it navigates a regulatory maelstrom…
Capricor Therapeutics, Inc. ( CAPR ) is currently at a pivotal juncture as it seeks to stabilize its position following significant stock declines and FDA scrutiny. The company's lead product, Deramio…
Capricor Therapeutics, Inc. ( CAPR ) is navigating a tumultuous period marked by regulatory scrutiny, investor concerns, and significant implications for its lead therapeutic product, Deramiocel. This…
Capricor Therapeutics, Inc. ( CAPR ) is navigating a challenging regulatory landscape after recent events have significantly impacted investor confidence and stock performance. The biopharmaceutical c…
Capricor Therapeutics, Inc. (CAPR) has been carving out a prominent position in the biopharmaceutical industry, specifically focusing on pivotal advancements in treatments for Duchenne muscular dystro…
Capricor Therapeutics (Ticker: CAPR) presents promising findings from its HOPE-2 Open-Label Extension study, highlighting significant advancements in the treatment of Duchenne muscular dystrophy (DMD)…
Capricor Therapeutics has achieved a significant milestone that advances its lead product, Deramiocel, aimed at treating Duchenne muscular dystrophy. Regulatory Milestone for Deramiocel The company su…
Advancements in Regenerative Medicine: Capricor Therapeutics' Pioneering Approach Capricor Therapeutics stands at the forefront of regenerative medicine, focusing on innovative treatments for cardiova…
Capricor Therapeutics Expands Focus on Cardiac Regenerative Medicine Capricor Therapeutics, a company dedicated to innovative treatments for cardiovascular diseases, announces its commitment to advanc…
Leadership Transition at FDA's Biologics Center Marks a Crucial Juncture for the Biopharmaceutical Sector The impending departure of Dr. Vinay Prasad as head of the FDA's Center for Biologics Evaluati…
FDA Faces Leadership Transition Amid Regulatory Challenges in Biopharmaceuticals The U.S. Food and Drug Administration (FDA) prepares for a significant leadership transition as Dr. Vinay Prasad announ…
Capricor Therapeutics Faces Regulatory Future Amidst Key FDA Leadership Change In a recent announcement, U.S. Food and Drug Administration (FDA) Commissioner Marty Makary reveals Dr. Vinay Prasad's de…
Capricor Therapeutics Faces Investor Skepticism Amid High Short Interest Capricor Therapeutics Inc. is currently grappling with a pronounced level of short interest that reflects a bearish sentiment a…
Capricor Therapeutics Faces High Short Interest Amid Market Sentiment Capricor Therapeutics Inc. is currently navigating a challenging market landscape characterized by a significant level of short in…
Capricor Therapeutics: Navigating the Complexities of Biotech Investment Amid Clinical Success Capricor Therapeutics finds itself at the forefront of a pivotal moment in the biotechnology sector, as t…
Capricor Therapeutics: Navigating Clinical Trials Amid Market Volatility Capricor Therapeutics, a company focused on developing innovative treatments for serious medical conditions, finds itself at th…
Capricor Therapeutics Advances in Cellular Therapy Research Capricor Therapeutics focuses on innovative cellular therapies to address significant health challenges, particularly in the realms of heart…
Capricor Therapeutics Advances in Cardiovascular Care with Promising Trial Results Capricor Therapeutics, Inc. (NASDAQ: CAPR) recently announces positive topline results from the Phase 3 HOPE-3 trial…
Capricor Therapeutics Advances Cell Therapy for Cardiac Conditions Capricor Therapeutics is making significant strides in the field of regenerative medicine, particularly focusing on cell therapy appl…
Capricor Therapeutics Advances Exosome-Based Drug Delivery Platform Amid Investor Concerns Capricor Therapeutics Inc., renowned for its pioneering work in regenerative medicine, is making strides with…
Capricor Therapeutics Advances Exosome-Based Drug Delivery Amid Investor Concerns Capricor Therapeutics Inc. is making strides in its exosome-based drug delivery platform, a key aspect of its innovati…
Capricor Therapeutics Strengthens Exosome-Based Drug Delivery Platform Despite Market Concerns Capricor Therapeutics Inc., a leader in the development of innovative treatments, recently unveils new da…
Capricor Therapeutics: Pioneering Cell Therapy Developments in Heart Disease Capricor Therapeutics continues to make strides in the field of regenerative medicine, particularly in the treatment of hea…
Capricor Therapeutics: Pioneering Cardiac Regenerative Medicine Capricor Therapeutics stands at the forefront of innovative therapies for cardiovascular diseases, with its proprietary product candidat…
Capricor Therapeutics: Pioneering Innovations in Rare Disease Therapies Capricor Therapeutics focuses on developing innovative therapies for rare diseases, particularly in the realm of cardiac and mus…
Capricor Therapeutics Prepares for Key Earnings Report Amid Promising Developments in Rare Disease Therapies Capricor Therapeutics, a biotech company focused on innovative treatments for rare diseases…
Capricor Therapeutics Faces Legal Scrutiny Over Deramiocel Data Disclosure Capricor Therapeutics, Inc. finds itself in the crosshairs of a federal securities lawsuit as Kuehn Law, PLLC initiates an in…
Capricor Therapeutics Advances Rare Disease Therapeutics Capricor Therapeutics Inc. makes significant strides in the biotechnology sector with its recent announcement regarding progress in its therape…
Capricor Therapeutics Advances Therapeutic Pipeline for Rare Diseases Capricor Therapeutics Inc. announces a significant milestone in its research and development efforts focused on rare diseases. The…
Capricor Therapeutics Faces Class Action Over Misleading Statements Regarding Deramiocel Capricor Therapeutics, Inc., a biotechnology company focused on developing innovative therapies for cardiac and…
### Capricor Therapeutics Faces Class Action Lawsuits Over Alleged Misleading Statements Capricor Therapeutics, Inc. is currently embroiled in multiple class action lawsuits filed by law firms allegin…
Capricor Therapeutics Faces Class Action Lawsuit Over Deramiocel Claims Capricor Therapeutics, Inc. is currently embroiled in a class action lawsuit initiated by law firm Levi & Korsinsky, LLP, on beh…
Capricor Therapeutics Faces Class Action Lawsuit Over Drug Misrepresentation Capricor Therapeutics, Inc. is currently embroiled in a class action lawsuit stemming from allegations of misleading commun…
Capricor Therapeutics Faces Class Action Lawsuit Over Misleading Drug Candidate Claims Capricor Therapeutics, Inc. is currently embroiled in a class action lawsuit filed against it, with significant i…
Capricor Therapeutics Faces Legal Challenges Over Allegations of Misleading Statements Capricor Therapeutics, Inc. is currently embroiled in legal disputes following allegations of misleading statemen…
Capricor Therapeutics Faces Legal Scrutiny Over Deramiocel Claims Capricor Therapeutics, Inc. is currently embroiled in a series of class action lawsuits stemming from allegations of misleading statem…
Capricor Therapeutics Faces Class Action Lawsuit Over Drug Development Misrepresentations Capricor Therapeutics, Inc., a clinical-stage biotechnology company, is currently embroiled in a class action…
Capricor Therapeutics Faces Multiple Class Action Lawsuits Over Alleged Securities Fraud Capricor Therapeutics, Inc. is currently embroiled in a series of class action lawsuits stemming from accusatio…
Capricor Therapeutics Faces Class Action Lawsuit Over Misleading Statements on Deramiocel Capricor Therapeutics, Inc. finds itself at the center of a class action lawsuit filed by Rosen Law Firm, a le…
Capricor Therapeutics Faces Legal Scrutiny Over Drug Development Transparency Capricor Therapeutics, Inc. is currently under scrutiny following allegations from shareholders regarding the company's ha…
Capricor Therapeutics Faces Legal Scrutiny Over Deramiocel Data Disclosure Capricor Therapeutics, a biotechnology firm focused on developing treatments for serious diseases, including cardiomyopathy r…
Capricor Therapeutics Faces Class Action Lawsuit Over Misleading Information Capricor Therapeutics, Inc. is currently embroiled in a class action lawsuit initiated by the Rosen Law Firm, which highlig…
Capricor Therapeutics Faces Class Action Over Deramiocel Misrepresentation Capricor Therapeutics, Inc. finds itself embroiled in a class action securities lawsuit initiated by Levi & Korsinsky, LLP. T…
Capricor Therapeutics Faces Class Action Lawsuit Over Misleading Statements Capricor Therapeutics, Inc., a biotechnology firm specializing in regenerative medicine, is embroiled in a class action laws…
Capricor Therapeutics Faces Class Action Lawsuit Over Allegations of Misleading Statements Capricor Therapeutics, Inc. is currently under scrutiny as the Schall Law Firm initiates a class action lawsu…
Capricor Therapeutics Faces Class Action Lawsuits Over Allegations of Misleading Statements Capricor Therapeutics, Inc. (NASDAQ: CAPR) is currently embroiled in multiple class action lawsuits followin…
Capricor Therapeutics Faces Class Action Lawsuit Amid Allegations of Misleading Investors Capricor Therapeutics, Inc. is currently embroiled in a class action lawsuit initiated by Levi & Korsinsky, LL…
Capricor Therapeutics Faces Class Action Lawsuit Over Deramiocel Claims Capricor Therapeutics, Inc. is currently facing significant legal challenges as a class action lawsuit is initiated against the…
Capricor Therapeutics Faces Legal Scrutiny Over Alleged Misleading Drug Efficacy Claims Capricor Therapeutics, Inc. is currently embroiled in legal challenges following allegations of misleading state…
Capricor Therapeutics Faces Class Action Lawsuit Over Alleged Misleading Statements Capricor Therapeutics, Inc. is currently embroiled in a class action lawsuit initiated by the Schall Law Firm, which…